← Search & browse all drugs

sodium iodohippurate (131I)

V09CX02

Forms & Strengths

Injection solution, diagnostic radiopharmaceutical
Typically supplied as 37 MBg (1 mCi) per vial at calibration time

Adult Dosing

Intravenous injection: 0.185 to 3.7 MBg (5 to 100 microcuries) for renal function studies
Dose adjusted based on specific diagnostic procedure (e.g., effective renal plasma flow or renography)

Pediatric Dosing

Intravenous injection: Dose calculated on a per-kilogram or body surface area basis, typically ranging from 0.05 to 0.15 MBg/kg
Minimum administered activity determined by gamma camera sensitivity and clinical protocol

Indications

Measurement of effective renal plasma flow (ERPF)
Radionuclide renography and assessment of individual kidney function
Evaluation of renal transplant patency and urinary tract obstruction

Mechanism of Action

Radiolabeled hippurate analogue transported rapidly across the renal tubular epithelium via organic anion transporters
Eliminated almost exclusively by tubular secretion with minimal glomerular filtration, allowing measurement of effective renal plasma flow

Contraindications

Hypersensitivity to iodinated compounds or any component of the formulation
Pregnancy, due to potential risks of ionizing radiation to the fetus
Breastfeeding (temporary discontinuation required)

Adverse Reactions

Hypersensitivity reactions (urticaria, rash, pruritus, anaphylaxis)
Nausea and flushing rarely reported
Injection site reactions

Drug Interactions

Probenecid inhibits renal tubular secretion, significantly altering effective renal plasma flow measurements
Drugs altering renal hemodynamics (e.g., NSAIDs, ACE inhibitors) may affect diagnostic test interpretation

Curated Content: Needs Vetting Before Put to Clinical Use